Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs KE Holdings Inc (BEKE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs KE Holdings Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while KE Holdings Inc trades at $15.75 (market cap $17.21B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 2.3× KE Holdings Inc's market cap, and KE Holdings Inc pays a 1.77% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | BEKE | |
|---|---|---|
Market Cap | $39.89B | $17.21B |
Sector | Health | Technology |
52-Week High | $491.22 | $20.36 |
52-Week Low | $278.09 | $14.26 |
Enterprise Value | $38.15B | $12.99B |
Dividend Yield | — | 1.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
BEKE trades at $15.57, up 2.1% today, with a bearish technical signal despite recent earnings beat. The company reported strong Q1 2026 results with EPS of $0.20 beating expectations of $0.14, driven by improved profitability despite lower revenue. Analyst consensus remains overwhelmingly bullish with 91.7% buy ratings, while technical indicators show oversold conditions suggesting potential reversal.
The outlook appears constructive given improving profitability and positive analyst sentiment, though risks include China's property market volatility and recent cash flow challenges. The stock's current valuation at P/E 35.6x reflects growth expectations, with potential upside if operational improvements continue.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About KE Holdings Inc
KE Holdings (Beike) is China’s leading platform for housing transactions and services. It operates the Lianjia brand and uses data-driven technology to facilitate home sales, rentals, and home renovation services.
Read more on BEKE →
